Abbott's freestyle libre® 3 integrated with automated insulin delivery system mylife™ loop in germany

First automated insulin delivery (aid) system in the world to work with abbott's freestyle libre® 3 sensor automated process streamlines and improves daily diabetes management for people who are on insulin therapy1 hybrid closed-loop system mylife™ loop incorporates technology from two partners: camdiab's algorithm automatically adjusts insulin dosage on ypsomed's insulin pump, mylife™ ypsopump®, based on accurate2, real-time glucose information from freestyle libre 3 sensor abbott park, ill., dec. 21, 2022 /prnewswire/ -- abbott (nyse: abt) today announced that its freestyle libre® 3 sensor is now compatible with the mylife™ loop solution from partners, ypsomed and camdiab, creating a smart, automated process to deliver insulin based on real-time glucose data.
ABT Ratings Summary
ABT Quant Ranking